Literature DB >> 21894176

The association of diabetes and positive prostate biopsy in a US veteran population.

K A Moses1, O A Utuama, M Goodman, M M Issa.   

Abstract

BACKGROUND: Several studies have shown a protective effect of diabetes mellitus (DM) on incidence of prostate cancer; however, the data are not consistent. Moreover, whether or not DM is associated with a positive result among patients referred for prostate biopsy due to abnormal PSA and/or abnormal digital rectal examination is not clear.
METHODS: A retrospective review of 3162 consecutive men who underwent prostate biopsy between January 2000 and July 2009 at the Atlanta Veterans Affairs Medical Center was performed. Men with positive and negative biopsies were compared for various demographic and clinical factors. The data were analyzed using logistic regression models with results expressed as adjusted odds ratios (ORs) with corresponding 95% confidence intervals (CI).
RESULTS: DM was associated with increased odds of positive biopsy in the overall cohort (OR 1.26, 95% CI: 1.01-1.55; P = 0.04). Subjects with DM had higher odds of more aggressive disease (Gleason ≥ 7) than those without the condition (OR 1.31, 95% CI: 0.98-1.74; P = 0.07). Race had no significant impact on these results.
CONCLUSIONS: In this large series of prostate biopsies, diabetes is associated with higher odds of positive biopsy and higher Gleason grade. More studies investigating the role of DM and its associated comorbidities in prostate carcinogenesis are needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894176     DOI: 10.1038/pcan.2011.40

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  12 in total

1.  The influence of comorbid conditions on racial disparities in endometrial cancer survival.

Authors:  Julie J Ruterbusch; Rouba Ali-Fehmi; Sara H Olson; Shawnita Sealy-Jefferson; Benjamin A Rybicki; Sharon Hensley-Alford; Mohamed A Elshaikh; Arthur R Gaba; Daniel Schultz; Adnan R Munkarah; Michele L Cote
Journal:  Am J Obstet Gynecol       Date:  2014-06-19       Impact factor: 8.661

2.  Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.

Authors:  Melissa A Babcook; Sanjeev Shukla; Pingfu Fu; Edwin J Vazquez; Michelle A Puchowicz; Joseph P Molter; Christine Z Oak; Gregory T MacLennan; Chris A Flask; Daniel J Lindner; Yvonne Parker; Firouz Daneshgari; Sanjay Gupta
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

3.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

4.  Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

Authors:  Jeffrey Shevach; Emily Jane Gallagher; Teena Kochukoshy; Victoria Gresia; Manpreet Brar; Matthew D Galsky; William K Oh
Journal:  Front Oncol       Date:  2015-06-15       Impact factor: 6.244

5.  Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.

Authors:  Yoko Tsutsumi; Takashi Nomiyama; Takako Kawanami; Yuriko Hamaguchi; Yuichi Terawaki; Tomoko Tanaka; Kunitaka Murase; Ryoko Motonaga; Makito Tanabe; Toshihiko Yanase
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

Review 6.  Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.

Authors:  Tashihiko Yanase; Takako Kawanami; Tomoko Tanaka; Makito Tanabe; Takashi Nomiyama
Journal:  Reprod Med Biol       Date:  2017-06-12

7.  The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.

Authors:  Huan Xu; Shi Fu; Qi Chen; Meng Gu; Juan Zhou; Chong Liu; Yanbo Chen; Zhong Wang
Journal:  Oncotarget       Date:  2017-05-09

Review 8.  CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis.

Authors:  Jakob Starup-Linde; Oystein Karlstad; Stine Aistrup Eriksen; Peter Vestergaard; Heleen K Bronsveld; Frank de Vries; Morten Andersen; Anssi Auvinen; Jari Haukka; Vidar Hjellvik; Marloes T Bazelier; Anthonius de Boer; Kari Furu; Marie L De Bruin
Journal:  Curr Drug Saf       Date:  2013-11

Review 9.  Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update.

Authors:  Noboru Hara
Journal:  Exp Diabetes Res       Date:  2012-06-26

Review 10.  A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus.

Authors:  Danielle Crawley; Florence Chamberlain; Hans Garmo; Sarah Rudman; Björn Zethelius; Lars Holmberg; Jan Adolfsson; Par Stattin; Paul Carroll; Mieke Van Hemelrijck
Journal:  Ecancermedicalscience       Date:  2018-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.